Jiang-Fan Chen Selected Research

Caffeine (No Doz)

11/2020	Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?
1/2020	Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms.
2/2019	Caffeine attenuates brain injury but increases mortality induced by high-intensity blast wave exposure.
1/2019	Adenosine and Sleep.
1/2018	Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum.
1/2017	Caffeine preferentially protects against oxygen-induced retinopathy.
1/2017	Adenosine receptors and caffeine in retinopathy of prematurity.
1/2014	Adenosine receptor control of cognition in normal and disease.
3/2013	Caffeine consumption and risk of dyskinesia in CALM-PD.
7/2011	Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jiang-Fan Chen Research Topics

Disease

28	Parkinson Disease (Parkinson's Disease) 04/2022 - 02/2002
13	Brain Injuries (Brain Injury) 02/2019 - 10/2004
12	Inflammation (Inflammations) 01/2019 - 01/2003
9	Hypoxia (Hypoxemia) 01/2017 - 06/2002
9	Huntington Disease (Huntington's Disease) 07/2015 - 05/2007
7	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2022 - 12/2007
7	Neuroinflammatory Diseases 01/2020 - 01/2008
7	Traumatic Brain Injuries (Traumatic Brain Injury) 02/2019 - 04/2010
7	Dyskinesias (Dyskinesia) 03/2013 - 11/2003
6	Cognitive Dysfunction 01/2018 - 11/2013
6	Schizophrenia (Dementia Praecox) 12/2015 - 09/2006
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2022 - 02/2009
5	Multiple Sclerosis 02/2022 - 12/2007
5	Wounds and Injuries (Trauma) 02/2019 - 06/2002
5	Stroke (Strokes) 01/2019 - 12/2007
5	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2018 - 12/2010
5	Nervous System Diseases (Neurological Disorders) 02/2009 - 12/2005
4	Demyelinating Diseases (Demyelinating Disease) 02/2022 - 02/2009
4	Myopia 11/2021 - 01/2011
4	Hyperoxia 01/2021 - 12/2015
4	Brain Ischemia (Cerebral Ischemia) 02/2017 - 10/2009
4	Pathologic Neovascularization 01/2017 - 12/2010
3	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 12/2007
3	Blindness (Hysterical Blindness) 01/2018 - 01/2017
3	Fibrosis (Cirrhosis) 10/2016 - 08/2006
3	Psychotic Disorders (Schizoaffective Disorder) 07/2007 - 06/2003
2	Blast Injuries 02/2019 - 02/2010
2	Sepsis (Septicemia) 01/2019 - 10/2006
2	Sleep Wake Disorders 01/2019 - 01/2019
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2019 - 01/2016
2	Synucleinopathies 01/2018 - 01/2016
2	Retinal Neovascularization 01/2018 - 12/2010
2	Infarction (Infarctions) 02/2017 - 10/2004
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 02/2017 - 11/2009
2	Neurobehavioral Manifestations 12/2015 - 04/2013
2	Gliosis 07/2015 - 11/2013
2	Arthritis (Polyarthritis) 01/2015 - 01/2003
2	Body Weight (Weight, Body) 10/2012 - 07/2009
2	Hyperemia 05/2009 - 10/2008
2	Neoplasms (Cancer) 08/2006 - 07/2004
2	Ischemia 10/2004 - 09/2003
1	Sudden Unexpected Death in Epilepsy 01/2022
1	COVID-19 01/2021

Drug/Important Bio-Agent (IBA)

48	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 04/2022 - 06/2002
33	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 06/2002
21	Caffeine (No Doz)FDA LinkGeneric 11/2020 - 09/2002
20	Purinergic P1 Receptors (Adenosine Receptor)IBA 10/2019 - 06/2002
9	Glutamic Acid (Glutamate)FDA Link 12/2015 - 01/2008
8	Levodopa (L Dopa)FDA LinkGeneric 01/2020 - 02/2002
8	Dopamine (Intropin)FDA LinkGeneric 12/2015 - 12/2003
6	Oxygen (Dioxygen)IBA 01/2021 - 12/2010
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2002
6	CytokinesIBA 01/2019 - 10/2004
5	Retinaldehyde (Retinal)IBA 01/2021 - 12/2010
4	Adenosine A2 Receptor AntagonistsIBA 04/2022 - 12/2006
4	CollagenIBA 11/2021 - 01/2013
4	Small Interfering RNA (siRNA)IBA 01/2021 - 08/2006
4	istradefyllineIBA 01/2020 - 07/2015
4	Pharmaceutical PreparationsIBA 01/2011 - 09/2006
4	Neuroprotective AgentsIBA 03/2008 - 11/2003
4	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 03/2008 - 09/2002
3	EnzymesIBA 11/2021 - 09/2007
3	Adenosine A1 ReceptorIBA 02/2017 - 12/2015
3	Dopamine Agonists (Dopamine Agonist)IBA 04/2015 - 12/2003
3	Neurotransmitter Agents (Neurotransmitter)IBA 05/2012 - 09/2009
3	LigandsIBA 01/2011 - 12/2007
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2011 - 09/2006
3	Amphetamine (Amfetamine)FDA LinkGeneric 07/2007 - 06/2003
2	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA 01/2022 - 10/2019
2	Kainic Acid (Kainate)IBA 01/2022 - 11/2018
2	Adenosine KinaseIBA 01/2022 - 01/2008
2	AcidsIBA 01/2021 - 01/2003
2	Coffee FDA Link 02/2019 - 03/2013
2	Ethanol (Ethyl Alcohol)IBA 01/2019 - 09/2006
2	SynucleinsIBA 01/2018 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 01/2016 - 09/2006
2	MicroRNAs (MicroRNA)IBA 03/2015 - 02/2014
2	histone H3 trimethyl Lys4IBA 03/2015 - 01/2015
2	ChromatinIBA 03/2015 - 01/2012
2	ZM 241385 (ZM241385)IBA 04/2010 - 08/2006
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010 - 10/2006
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 02/2010 - 12/2005
2	Purinergic P1 Receptor AntagonistsIBA 05/2009 - 08/2006
1	Natalizumab (Tysabri)FDA Link 02/2022
1	5-iodotubercidinIBA 01/2022
1	alpha-SynucleinIBA 01/2022
1	RolipramIBA 11/2021
1	Adenosine Monophosphate (AMP)IBA 11/2021
1	Ribonucleases (Ribonuclease)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Activin Receptors (Activin Receptor)IBA 01/2021
1	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2021
1	Adenosine Triphosphate (ATP)IBA 01/2021
1	Myelin-Oligodendrocyte GlycoproteinIBA 10/2019

Therapy/Procedure

8	Therapeutics 01/2017 - 01/2003
3	Punctures 01/2019 - 10/2006
3	Drug Therapy (Chemotherapy) 09/2009 - 12/2007
2	Ligation 01/2019 - 10/2006
2	Lasers (Laser) 01/2018 - 10/2008
2	Electroacupuncture 02/2017 - 01/2015